- Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely
-
Nishikimi , Tate S, Kato K, Matsuoka A, Shozu M
- KMID: 2500402
- J Gynecol Oncol.
- 2020 Jan;31(1):e3.
- doi: 10.3802/jgo.2020.31.e3
Objective: This study was performed to examine the safety of bowel resection and upper abdominal surgery in patients with advanced ovarian cancer performed by gynecologic oncologists after training in a... -
- CITED
-
- Close
- SHARE
-
- Close
- Surgical anatomy of the common iliac veins during para-aortic and pelvic lymphadenectomy for gynecologic cancer
-
Kato K, Tate S, Nishikimi , Shozu M
- KMID: 1811190
- J Gynecol Oncol.
- 2014 Jan;25(1):64-69.
- doi: 10.3802/jgo.2014.25.1.64
OBJECTIVE: Compression of the left common iliac vein between the right common iliac artery and the vertebrae is known to be associated with the occurrence of left iliofemoral deep vein... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictors of postoperative pancreatic fistula after splenectomy with or without distal pancreatectomy performed as a component of cytoreductive surgery for advanced ovarian cancer
-
Nishikimi K, Tate S, Matsuoka A, Otsuka S, Shozu M
- KMID: 2536992
- J Gynecol Oncol.
- 2022 May;33(3):e30.
- doi: 10.3802/jgo.2022.33.e30
Objective Splenectomy with or without distal pancreatectomy is occasionally performed during cytoreductive surgery for advanced ovarian cancer. We investigated pre-, intra-, postoperative risk factors and predictors of clinically relevant postoperative pancreatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
-
Tate S, Nishikimi K, Matsuoka A, Otsuka S, Kato K, Takahashi Y, Shozu M
- KMID: 2526298
- J Gynecol Oncol.
- 2021 Jan;32(1):e8.
- doi: 10.3802/jgo.2021.32.e8
Objective: We investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan for platinum-refractory/resistant ovarian or primary peritoneal cancer. Methods: We enrolled patients with ovarian or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer
-
Tate S, Nishikimi , Kato K, Matsuoka A, Kambe M, Kiyokawa T, Shozu M
- KMID: 2500482
- J Gynecol Oncol.
- 2020 Apr;31(3):e34.
- doi: 10.3802/jgo.2020.31.e34
Objective: This study aimed to evaluate the presence of pathological residual tumor (pRT) in each initial disseminated site after neoadjuvant chemotherapy (NACT) to assess the appropriate surgical margins during interval... -
- CITED
-
- Close
- SHARE
-
- Close
